2024-11-29 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison & Outperformance:**

Eli Lilly and Co. (LLY), a leading pharmaceutical company, significantly outperformed the S&P 500 (VOO) over the period analyzed.  The cumulative return for LLY is 624.48%, while the S&P 500's cumulative return is 128.86%. This represents a difference of 495.6%, placing LLY at the 73.7th percentile of its historical relative performance compared to the S&P 500.  The provided data shows consistently high alpha values, indicating significant outperformance relative to the market benchmark.  The beta values, while fluctuating, generally remain above 1, suggesting higher volatility than the market but also higher potential returns.

**2. Recent Price Movement:**

* **Closing Price:** $788.19 (Last Market: $788.61)
* **5-Day Moving Average:** $766.09
* **20-Day Moving Average:** $784.39
* **60-Day Moving Average:** $865.17

The price is currently below all three moving averages, suggesting a potential short-term downtrend.  The significant gap between the current price and the 60-day moving average is noteworthy.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 48.13 -  Suggests the stock is neither overbought nor oversold, but leaning slightly towards bearish territory.
* **PPO (Percentage Price Oscillator):** 0.47 - A positive value indicates bullish momentum, although relatively weak.
* **20-Day Relative Divergence:** -9.0% - Indicates a recent short-term downward trend.
* **Expected Return:** 578.1% - This represents a significant projected outperformance of the S&P 500 over the long term (2+ years)  assuming continued strong performance.  The high expected return should be viewed cautiously considering the inherent volatility in the stock market. The recent price drop could be contributing to a lower short-term expectation.


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility:

* **Revenue:** Revenue generally shows a growth trend, although there's a dip in Q1 2024.  The most recent quarter (Q3 2024) shows a notable increase compared to Q1 and Q2 2024.
* **EPS:** EPS fluctuates significantly. Q2 2024 shows a strong increase compared to the preceding quarters.  Noteworthy is the negative EPS reported in Q4 2023 and Q3 2024, which are a significant departure from the positive figures reported in the other quarters.  More context is needed to properly interpret these swings.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, with a notable increase in the most recent quarter. Profit margins remain consistently high, suggesting strong profitability.
* **Capital and Profitability:** Equity has shown a steady increase, although there is significant fluctuation in Return on Equity (ROE). The very high ROE in Q2 2024 is striking and needs further investigation to understand the underlying factors.  The negative ROE in Q3 2023 is also a key area needing further scrutiny.


**6. News and Recent Issues:**

* **Recent Earnings News:**  The report needs the latest two days' earning news to provide a complete picture.
* **Market Outlook & Analyst Opinions:** This section requires additional data from recent market analyses and analyst reports to be complete.


**7. Overall Analysis:**

LLY has demonstrated substantial outperformance compared to the S&P 500 over the historical period analyzed.  However, recent price action suggests a potential short-term downturn. The company exhibits high profitability and strong revenue growth, although some volatility is present in recent earnings data, particularly concerning the EPS.  Technical indicators suggest a neutral to slightly bearish short-term outlook. The high expected return projection should be considered cautiously given market volatility and requires further supporting information. A comprehensive analysis needs additional data, particularly regarding recent news, analyst opinions, and a deeper dive into the factors contributing to the fluctuations in ROE and EPS.  Further investigation into the causes of the negative EPS in Q4 2023 and Q3 2024 is crucial for a more complete assessment.


**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  It's crucial to conduct thorough due diligence and consult with a financial advisor before making any investment decisions.  The analysis is limited by the provided data and may not capture all relevant factors influencing LLY's performance.
